Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million.

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

The shares of Cassava Sciences Inc  (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.

Cassava Sciences Stock's Bull Signal Has Never Been Wrong

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offering. The closing of the offering is expected to occur on or about November 22, 2022, subject to the satisfaction of customary closing conditions.

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

Bed Bath & Beyond

Credit Suisse

LM Ericsson Telefon

Hyzon Motors

TuSimple Holdings

High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.

7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022

In today's mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon's session is Cassava Sciences (NASDAQ: SAVA ).

Why Is Cassava Sciences (SAVA) Stock Up Today?

Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company's third-quarter earnings and a stark warning to short sellers. During Q3, the company reported a net loss of $20.3 million, equivalent to an EPS loss of 51 cents per share.

Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers

– $174.7 Million Cash and Cash Equivalents at September 30, 2022 –

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page complaint alleges that the Defendants' disinformation campaign caused a precipitous decline in Cassava Sciences' stock price, a multi-billion dollar decline in its market capitalization, and delayed the Company's work in developing a treatment for Alzheimer's disease.

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

BioVie Inc

Eli Lilly

Prothena

Roche Holding AG

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

Shares of Cassava Sciences (NASDAQ: SAVA ) declined by as much as 12% today but have since recovered to the $35 range, down about 4%. This was most likely attributed to the release of an article by Probes Reporter.

Why Is Cassava Sciences (SAVA) Stock Down 10% Today?

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA).

CASSAVA SCIENCES INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

AUSTIN, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel. This is a newly created position, reporting to Remi Barbier, President & CEO.

Cassava Sciences Announces Expansion of Leadership Team

Akero Therapeutics Inc

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Immuneering Corp

Novavax

Value Line

Ventyx Biosciences

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimer's disease ( AD ) drug, simufilam. The trial will be eligible for patients who complete either one of its ongoing Phase 3 studies.

SAVA Stock Alert: Cassava Sciences Extends Trial

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the initiation of an open-label extension study. This study is designed to provide no-cost access to simufilam, an investigational drug, to patients with Alzheimer's disease who complete either one of Cassava Sciences' on-going Phase 3 studies, which are double-blind, placebo-controlled trials.

Cassava Sciences Announces Initiation of an Open-label Extension Study

Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).

How High Can SAVA Stock Go Once the Controversy Clears?

This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science.

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.

Should you buy Cassava Sciences as the stock continue to soar

Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCMKTS: ESALY ) of Japan, showed a decline in symptoms among 1,795 patients with early Alzheimer's, a brain disease impacting nearly one-third of Americans ages 85 and older.

Why Is Cassava Sciences (SAVA) Stock Heating Up Today?

Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassava.

5 Investors Betting Big on Cassava (SAVA) Stock

Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022.

Cassava: High Risk Speculative Play With Enormous Potential

Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case on Cassava following the initiation of an investigation last November.

The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher

The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data appeared first on Investor's Business Daily.

Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data

Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%.

News for Cassava Sciences Inc Stock (SAVA)